Showing results (71-80 of 81) with videos related to
Sort By:
Pageof 9
Cancer Science|December 24, 2010
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancerTakuji Okusaka, Junji Furuse, Akihiro Funakoshi, et al.Journal of Gastroenterology|May 29, 2004
Enhanced gastric emptying of a liquid gastric load in mice lacking cholecystokinin-B receptor: a study of CCK-A,B, and AB receptor gene knockout miceKyoko Miyasaka, Minoru Ohta, Setsuko Kanai, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 13, 2007
Cholecystokinin-A receptors regulate photic input pathways to the circadian clockTakao Shimazoe, Mitsutaka Morita, Shinichiro Ogiwara, et al.The Journal of Nutrition|April 2, 2002
Energy metabolism and turnover are increased in mice lacking the cholecystokinin-B receptorKyoko Miyasaka, Mineko Ichikawa, Minoru Ohta, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 5, 2003
[Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer]Toshihiko Sumii, Akihiro Funakoshi, Tetsuhide Ito, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 15, 2008
[Phase I/II study of combination chemotherapy with gemcitabine and UFT for advanced pancreatic cancer in a multi-center trial]Toshihiko Sumii, Akihiro Funakoshi, Kazuhiro Mizumoto, et al.Diabetes|February 24, 2012
Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokininSatoshi Miyamoto, Kenichi Shikata, Kyoko Miyasaka, et al.ESMO Open|August 2, 2017
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, et al.The Lancet. Oncology|February 11, 2011
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 studyHedy L Kindler, Tatsuya Ioka, Dirk J Richel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2013
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST studyHideki Ueno, Tatsuya Ioka, Masafumi Ikeda, et al.Pageof 9